The FDA has reprimanded Dexcel and its affiliate Edenbridge Pharmaceuticals for “false or misleading” promotional claims regarding its brand-name drug Hemady.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA scolds drugmaker for 'false or misleading' claims
